This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Endocardial Fibroelastosis심내막탄력섬유증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I42.4 (endocardial fibroelastosis) | Special Copayment Reduction: V127 (rare disease)
B. SynonymsEndocardial fibroelastosis | Congenital cardiomyopathy
C. Adult onsetLikelihood of first onset in adulthood: very low — endocardial fibroelastosis is a congenital heart disease that typically presents with heart failure in infancy (6 months~2 years of age). First diagnosis in adults is very rare, mainly occurring when a chronic course continues in patients who survived after diagnosis in infancy, or when an asymptomatic mild case is discovered incidentally after school age.
1. History1740 first described at autopsy → 1943 modern naming by Weinberg and Himelfarb → 1960s mumps virus association hypothesis → 2000s renewed attention to combined genetic and viral mechanisms.
2. CausesFetal viral infection (mumps, EBV, coxsackie), response to congenital left heart obstruction, genetics (TAZ, G4.5 gene, etc.), association with metabolic diseases.
3. GeneticsTAZ gene (Xq28, associated with Barth syndrome), mitochondrial gene variants, some autosomal recessive pedigrees reported.
4. General epidemiologyAbout 1 per 5,000 births. Trend toward decreased incidence after introduction of the mumps vaccine. Slightly more common in boys.
5. PathophysiologyAbnormal proliferation and differentiation of endocardial cells in the fetal period → accumulation of elastic and collagen fibers → impaired ventricular filling, dilated cardiomyopathy.
6. SymptomsTachypnea, feeding difficulty, failure to thrive, and cyanosis in infancy. Symptoms of congestive heart failure.
7. SignsCardiomegaly (displaced heart sounds), tachycardia, abnormal breath sounds, hepatomegaly. ECG left ventricular hypertrophy and ST changes; echocardiography dilated left ventricle and increased endocardial echogenicity.
8. ScreeningFollow-up when increased left ventricular echogenicity is found on prenatal ultrasound. Echocardiography in newborns with a family history. Indirect prevention by mumps vaccination.
9. DiagnosisEchocardiography (increased endocardial echogenicity, left ventricular dilation, reduced systolic function). Cardiac MRI. Genetic testing. Endocardial biopsy (noninvasive methods preferred).
10. TreatmentStandard heart failure treatment (digoxin, diuretics, ACE inhibitors). Long-term anticoagulation. Heart transplantation for refractory heart failure.
11. PrognosisHigh mortality (40~80% in the 1960s). Improved with modern intensive care. Some cases of spontaneous recovery. Relatively good prognosis after heart transplantation.
12. PreventionMumps MMR vaccination. Prevention of infection during pregnancy. Genetic counseling. Early diagnosis and initiation of treatment.
13. ReferencesNi J, et al. Viral infection of the myocardium in endocardial fibroelastosis. Circulation. 1997 … and 9 other papers

1. History

Endocardial fibroelastosis (EFE) has historically been one of the challenging problems of pediatric cardiology. The oldest description dates from 1740, when an autopsy recorded the finding that an infant's endocardium appeared abnormally thick and glossy white. In the 18th~19th centuries, many European physicians sporadically described similar autopsy findings, but no systematic classification was made.

In 1943, Weinberg and Himelfarb in the United States first used the modern name "endocardial fibroelastosis" and defined the disease as an independent clinical entity. They described in detail the characteristic pathologic finding of left ventricular endocardium thickened by elastic fibers and collagen fibers, giving a "milky porcelain" appearance.

Important epidemiologic observations were made in the 1960s. It was reported that mumps virus epidemics were temporally associated with an increase in endocardial fibroelastosis, and that EFE occurred more often in the children of mothers infected with mumps during pregnancy. In addition, experiments showing that inoculating chick embryos with mumps virus induced endocardial thickening supported the viral hypothesis. However, mumps virus was not identified in all EFE patients, so heterogeneity of causes was recognized.

After the introduction of the mumps vaccine (MMR) in the 1960s~70s, the incidence of EFE decreased markedly, further strengthening the mumps hypothesis. Since the 1990s, advances in molecular genetics have identified TAZ gene (Xq28) variants (the cause of Barth syndrome) and mitochondrial gene variants in some familial EFE. In the 2000s, advances in cardiac MRI improved the accuracy of antemortem EFE diagnosis, and early detection of EFE by prenatal fetal echocardiography became possible. Recently, the concept has been established that EFE is not a single disease but a common endocardial response pattern to various causes.

2. Causes

The causes of endocardial fibroelastosis are diverse and are broadly divided into primary (idiopathic) and secondary. Primary EFE is when no specific cause is identified, but it is understood as the combined action of genetic predisposition and fetal environmental factors. Secondary EFE occurs secondary to left heart obstructive lesions (aortic stenosis, coarctation of the aorta, hypoplastic left heart syndrome), myocardial infection, or metabolic diseases.

Viral infection hypothesis: The hypothesis that fetal or neonatal infection with mumps virus, Epstein-Barr virus (EBV), coxsackie B virus, or echovirus causes endocardial cell injury and promotes abnormal proliferation of elastic and collagen fibers. Evidence supporting this hypothesis: ① increased EFE after mumps epidemics, ② decreased EFE incidence after introduction of the MMR vaccine, ③ induction of endocardial thickening in chick embryo mumps infection experiments. However, it is controversial because detecting viral genomes in EFE tissue by molecular techniques is not always possible.

Hemodynamic (left heart obstruction) hypothesis: The main mechanism of secondary EFE, in which increased left ventricular pressure due to congenital left heart obstructive lesions (aortic stenosis, coarctation of the aorta, hypoplastic left heart syndrome) increases mechanical stress on the endocardium and triggers an elastic fiber proliferative response.

Genetic causes: TAZ gene (tafazzin, Xq28) variants are the cause of Barth syndrome, which combines EFE, dilated cardiomyopathy, skeletal myopathy, neutropenia, and growth impairment. Autosomal recessive or X-linked inheritance patterns are observed in some familial EFE, and variants in mitochondrial energy metabolism genes (TFAM, POLG) are also causes of EFE-related cardiomyopathy.

Association with metabolic diseases: EFE-like findings can occur in metabolic diseases such as glycogen storage disease (Pompe disease, GAA gene), mucopolysaccharidosis (MPS), and myxedema. Because each of these has specific treatments, differentiation is important.

3. Genetics

The genetics of endocardial fibroelastosis have not yet been fully elucidated. Familial EFE is estimated to account for about 10~15% of all cases, and various modes of inheritance have been reported.

The best-established genetic cause is variants in the TAZ (tafazzin) gene. The TAZ gene is located on the long arm of the X chromosome (Xq28) and encodes an acyltransferase involved in the synthesis of cardiolipin in the inner mitochondrial membrane. TAZ variants are the cause of Barth syndrome, which mainly in boys combines dilated cardiomyopathy/EFE, skeletal myopathy, neutropenia, failure to thrive, and 3-methylglutaconic aciduria. TAZ variants are X-linked recessive and are expressed in boys.

Variants in genes related to mitochondrial energy metabolism are also causes of EFE-related cardiomyopathy. Mitochondrial complex deficiencies (complexes I, III, IV), TFAM variants, POLG variants, etc. have been reported as causes of infantile dilated cardiomyopathy and EFE. These are transmitted by autosomal recessive or maternal inheritance (mitochondrial DNA variants). In some familial EFE, no specific molecular cause has been identified, and the search for additional causative genes is ongoing.

The currently recommended genetic testing strategy is NGS with a dilated cardiomyopathy and EFE panel, including TAZ, LMNA, MYH7, MYBPC3, TPM1, TNNT2, SCN5A, and mitochondrial genes. Metabolic causes are differentiated by serum 3-methylglutaconic acid, urine organic acids, serum lactate/pyruvate, and plasma amino acid testing.

4. General epidemiology

The prevalence of endocardial fibroelastosis varies greatly by era and region. Before the introduction of the mumps vaccine (before the 1960s), it was a major cause, with reports that about 10~15% of children who died of heart disease had EFE, but its incidence decreased markedly after introduction of the mumps MMR vaccine.

The current estimated prevalence is reported as about 1 per 5,000~8,000 births, but it varies by diagnostic criteria and region. It is slightly more common in boys (male:female = about 1.5:1), which partly reflects X-linked genetic causes (TAZ variants, etc.). The age of onset is mainly infancy (6 months~2 years of age), and in this age group it is one of the main causes of asymptomatic heart failure. Cases detected prenatally by fetal echocardiography are also increasing.

No clear racial or ethnic differences have been reported, but incidence is higher in regions with low mumps vaccination rates. EFE is secondarily present in about 30~40% of congenital left heart obstructive lesions (especially hypoplastic left heart syndrome). Primary EFE is more common than secondary EFE. Familial occurrence is estimated at about 10~15%, and occurrence among brothers is recognized especially in Barth syndrome families.

In Korea, EFE is registered as a rare disease eligible for Special Copayment Reduction (V127). Domestic epidemiologic data are very limited, but incidence is presumed to be on a declining trend with the spread of the MMR vaccine.

5. Pathophysiology

The core of the pathophysiology of endocardial fibroelastosis is abnormal transition and proliferation of the endocardial cells that make up the endocardium, and excessive synthesis of connective tissue (elastic fibers and collagen fibers), in the fetal period or infancy.

Endocardial cell mechanism: In normal cardiac development, endocardial cells differentiate into myocardial interstitial cells through endothelial-to-mesenchymal transition (EndMT) and contribute to heart development. In EFE, this process abnormally persists and is amplified, so endocardial cells excessively transition into mesenchymal cells, and synthesis of elastic fibers (elastin) and type I and III collagen increases. As a result, the endocardium becomes thickly fibrosed and impedes ventricular relaxation.

Virus-induced mechanism: Mumps virus directly infects fetal cardiac cells (cardiomyocytes, endocardial cells), causing cell death and cytokine secretion, and cytokines such as TGF-β, IL-1β, and TNF-α are thought to promote EndMT and induce fibroblast activation. The interleukin-1β signaling pathway and the TGF-β1 signaling pathway are being studied as the key molecular pathways of endocardial thickening in EFE.

Hemodynamic mechanism (secondary): When left ventricular pressure rises in left heart obstructive lesions, the endocardium is exposed to sustained mechanical stress. Mechanical stress activates TGF-β secretion by endocardial cells and EndMT, promoting fibroproliferation. This mechanism explains why left heart obstructive lesions and EFE coexist in secondary EFE.

Mechanism of reduced cardiac function: The thick fibrous endocardium physically limits ventricular relaxation, and myocardial contractility also declines as fibrosis extends into the myocardial layer. A dilated cardiomyopathy pattern appears, with left ventricular enlargement and reduced systolic function. In some cases, endocardial fibrosis involves the tendinous valve apparatus of the atrioventricular valve (mitral valve), causing mitral regurgitation and further worsening cardiac function.

6. Symptoms

Endocardial fibroelastosis mainly presents with symptoms of heart failure in infants between 6 months and 2 years of age. Some cases are discovered incidentally on prenatal fetal echocardiography, and rarely it presents as acute heart failure within the first few weeks of life.

Respiratory symptoms: The most common initial symptom is tachypnea. Parents report that the child breathes faster than usual, tires easily during feeding, and has difficulty breathing. Sweating during feeding and cyanosis (especially during feeding or crying) may occur. It is sometimes mistaken for recurrent lower respiratory tract infections (bronchiolitis, pneumonia) or asthma-like symptoms, delaying recognition of a cardiac cause.

Feeding difficulty and failure to thrive: Because of reduced cardiac output and increased work of breathing, infants tire easily during feeding and cannot take enough milk. This leads to poor weight gain and failure to thrive, and EFE is sometimes diagnosed when infants visit a pediatrician with these as the chief complaint.

Presentation with acute heart failure: In some infants, acute heart failure is triggered by a respiratory infection (especially respiratory syncytial virus, RSV, infection) and is diagnosed for the first time. In such cases, serious symptoms such as rapid breathing, tachycardia, hypoxia, pallor or cyanosis, and decreased consciousness may occur.

Arrhythmias: Ventricular arrhythmias (premature ventricular contractions, ventricular tachycardia) or complete atrioventricular block may occur, and arrhythmias may worsen especially during or after surgery. In some cases, SVT (paroxysmal supraventricular tachycardia) occurs and aggravates EFE.

Asymptomatic detection: When increased left ventricular echogenicity, left ventricular enlargement, or reduced systolic function is found on prenatal fetal echocardiography, cardiologic evaluation is performed immediately after birth. Mild EFE may be asymptomatic and discovered incidentally on chest X-ray or echocardiography at school age or later.

7. Signs

The physical signs of endocardial fibroelastosis appear as the typical pattern of congestive heart failure and cardiomegaly.

Cardiovascular signs: Tachycardia (heart rate > 150/min or more) is almost always present. Because of cardiomegaly, the apical impulse is displaced to the left and downward. S3 (third heart sound) or S4 (fourth heart sound) may be heard. When mitral regurgitation is present, a systolic murmur is heard at the apex. Peripheral pulses may be weak and blood pressure low (reduced cardiac output).

Respiratory signs: Signs of accessory respiratory muscle use, such as tachypnea, intercostal retractions, and nasal flaring, appear. Crackles may be heard at the lung bases (pulmonary venous congestion and interstitial edema).

Signs of systemic congestion: Hepatomegaly appears due to right heart failure or tricuspid regurgitation. Peripheral edema is relatively rare in infants. Diaphoresis is a characteristic symptom of infant heart failure and is prominent during feeding or crying.

ECG findings: Left ventricular hypertrophy (tall R waves: ≥25 mm in V5 and V6, or deep S waves in V1), left axis deviation, ST segment abnormalities (depression or elevation), and T wave inversion (V4-V6) are characteristic. Atrial fibrillation, premature ventricular contractions, and conduction disorders may also be observed.

Echocardiographic findings: Markedly increased echogenicity of the left ventricular endocardium (a bright endocardial line) is characteristic. The left ventricle is spherically enlarged, wall thickness is normal or increased, and left ventricular systolic function is reduced (decreased LVEF). Abnormal mitral valve structure and regurgitation may be present. These findings can also be identified on prenatal echocardiography.

8. Screening

Newborn screening of the general population for endocardial fibroelastosis is currently not recommended. However, screening strategies for high-risk groups are important.

Prenatal fetal echocardiography screening: When increased echogenicity of the left ventricular endocardium, left ventricular enlargement, or reduced myocardial systolic function is observed on the detailed fetal ultrasound around 20 weeks of gestation, EFE is suspected and the patient is referred to a fetal cardiology specialist. In high-risk pregnant women with a family history of congenital heart abnormalities, mumps or EBV infection during pregnancy, diabetes, etc., detailed examination including fetal echocardiography is recommended.

Family screening for familial EFE: In Barth syndrome families (with confirmed TAZ variants), whether newborn boys are affected is determined early by TAZ gene testing or urine 3-methylglutaconic acid testing. When there is a family history of dilated cardiomyopathy or EFE, echocardiography and ECG follow-up from the neonatal period are recommended.

Mumps vaccination: Universal MMR vaccination contributes to the prevention of mumps virus-related EFE. Pregnant women who have completed the second MMR dose have a low risk of transmitting the virus to the fetus. In unvaccinated or non-immune pregnant women with a history of mumps exposure, fetal echocardiography follow-up is needed.

Differential diagnosis in unexplained infant heart failure: In infant heart failure of unknown cause, when increased echogenicity of the left ventricular endocardium is identified on echocardiography, differential diagnostic testing including for EFE is carried out. Serum enzyme and organic acid tests are performed to differentiate metabolic diseases (Pompe, Barth).

9. Diagnosis

The diagnosis of endocardial fibroelastosis is made by integrating clinical history, echocardiography, cardiac MRI, genetic and metabolic testing, and, when needed, endocardial biopsy.

Echocardiography (TTE): The primary diagnostic tool. Characteristic findings: ① diffuse echobright endocardium of the left ventricle, ② spherical LV enlargement, ③ reduced left ventricular systolic function (decreased LVEF, decreased fractional shortening), ④ mitral regurgitation, ⑤ left atrial enlargement. The presence of congenital obstructive lesions that require differentiation (aortic stenosis, coarctation of the aorta) is checked by Doppler. These findings can also be identified on prenatal fetal echocardiography, making prenatal diagnosis possible.

Cardiac MRI (CMR): Precisely evaluates endocardial thickening, the extent of fibrosis, and myocardial function. Late gadolinium enhancement (LGE) visualizes subendocardial fibrosis. Fetal MRI can also be used for prenatal diagnosis. Cardiac MRI also helps differentiate similar diseases such as dilated cardiomyopathy.

Genetic and metabolic testing: TAZ gene testing (in boys, when Barth syndrome is suspected). Urine organic acids (3-methylglutaconic acid, 3-methylglutaric acid), plasma acylcarnitines. Serum acid maltase (GAA) activity (to differentiate Pompe). Serum lactate/pyruvate, mitochondrial gene panel. Dilated cardiomyopathy gene panel NGS.

Endomyocardial biopsy (EMB): Allows histopathologic confirmation (proliferation of endocardial elastic and collagen fibers), but because of the risk of an invasive procedure in infants, it is considered when diagnosis is not possible by noninvasive methods. Pathologic findings: bundling of elastic fibers in the endocardium (increased elastin), collagen fiber proliferation, increased endocardial thickness, and hypertrophy and necrosis of cardiomyocytes.

Chest X-ray: Cardiomegaly (cardiothoracic ratio > 0.55 or more) and findings of pulmonary venous congestion (increased vascular markings, interstitial edema) are identified. These findings are nonspecific but provide the first clue to a cardiac abnormality.

10. Treatment

Treatment of endocardial fibroelastosis is based on standard pediatric heart failure treatment, combined with cause-specific treatment when an underlying cause is identified.

Standard heart failure pharmacotherapy: Digoxin has traditionally played an important role in the treatment of EFE. It contributes to symptom improvement by increasing myocardial contractility and controlling heart rate, and because some studies have reported that long-term digoxin administration aids spontaneous recovery of EFE, administration for at least 2~3 years is recommended. ACE inhibitors (enalapril, captopril) are included in standard treatment for their afterload reduction and inhibition of cardiac remodeling. Diuretics (furosemide, spironolactone) are used to control pulmonary and systemic congestion. Beta-blockers (carvedilol) can be added stepwise once heart failure has stabilized.

Anticoagulation: Anticoagulation (low-molecular-weight heparin, followed by warfarin) is given to patients with reduced left ventricular function or when an intraventricular thrombus is identified. When warfarin monitoring is difficult in infants, low-molecular-weight heparin (enoxaparin) is used.

Cause-specific treatment: In Pompe disease (GAA deficiency), enzyme replacement therapy with alglucosidase alfa is effective in reducing myocardial accumulation. In Barth syndrome (TAZ variants), nutritional support (L-carnitine supplementation) and infection prevention are important.

Heart transplantation: When the disease is refractory to maximal medical therapy and has progressed to end-stage heart failure, heart transplantation is the only definitive treatment. The prognosis after pediatric heart transplantation is relatively good compared with adults, with reported 1-year survival of 85% and 5-year survival of 70~75%. Recurrence of EFE after transplantation is rare.

11. Prognosis

The prognosis of endocardial fibroelastosis varies greatly depending on the timing of diagnosis, severity, underlying cause, and response to treatment. Before the introduction of the mumps vaccine (1960s), the prognosis of EFE was poor, with mortality reaching 40~80% within 2 years of diagnosis. With advances in modern intensive care and heart transplantation, the prognosis has improved greatly.

Cases of spontaneous recovery: In some EFE patients (about 10~20%), spontaneous or complete recovery with normalization of cardiac function under appropriate heart failure treatment has been reported. This phenomenon is known to be more common especially in mumps virus-related EFE, and there is a hypothesis that long-term digoxin administration contributes to it. Spontaneous recovery proceeds over months to years, and follow-up for several years is needed even after recovery.

Poor prognostic factors: Markedly reduced left ventricular function at diagnosis (LVEF < 25%), severe left ventricular enlargement, accompanying mitral regurgitation, arrhythmias (complete atrioventricular block, ventricular tachycardia), early onset (within 6 months of age), and familial occurrence (genetic cause) are poor prognostic factors. Barth syndrome-related EFE has a more complex prognosis because of multiorgan involvement (susceptibility to infection due to neutropenia). In secondary EFE (with left heart obstructive lesions), the prognosis is determined by the outcome of treatment of the underlying cardiac structural abnormality.

Long-term follow-up: Even in patients whose cardiac function has recovered with treatment response, some may have recurrence of reduced cardiac function or develop atrial fibrillation in adolescence or adulthood, so long-term follow-up is essential. Echocardiography, ECG, and BNP are followed regularly, and drug doses need adjustment with growth.

12. Prevention

The approach to prevention of endocardial fibroelastosis differs by cause.

Mumps vaccine (MMR vaccination): The most effective method of preventing mumps virus-related EFE. Universal MMR vaccination, with the first dose at 12~15 months and the second at 4~6 years of age, has contributed greatly to the decrease in EFE incidence. To prevent mumps infection during pregnancy, checking mumps antibodies in women of childbearing age and MMR vaccination before pregnancy if unvaccinated are recommended. Because the MMR vaccine is a live vaccine, vaccination during pregnancy is contraindicated.

Genetic counseling: For families with Barth syndrome (TAZ variants) or with a family history of dilated cardiomyopathy/EFE, genetic counseling provides information on options such as prenatal genetic testing and preimplantation genetic testing (PGT) when planning a pregnancy.

Prevention of infection during pregnancy: General hygiene rules (handwashing, avoiding contact with infected people) are important to prevent infection during pregnancy not only with mumps but also with EFE-related viruses such as coxsackievirus and EBV.

Early diagnosis and treatment: When an infant has unexplained cardiomegaly, tachypnea, or feeding difficulty, performing echocardiography early to diagnose EFE quickly and start treatment is key to increasing the likelihood of recovery of cardiac function.

13. References

  1. Ni J, Bowles NE, Kim YH, et al. Viral infection of the myocardium in endocardial fibroelastosis: molecular evidence for the role of mumps virus as an etiologic agent. Circulation. 1997;95(1):133-139. DOI: 10.1161/01.CIR.95.1.133. PMID: 8994428.

  2. Lurie PR. Changing concepts of endocardial fibroelastosis. Cardiol Young. 2010;20(2):115-123. DOI: 10.1017/S1047951109991521. PMID: 20003617.

  3. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-1876. DOI: 10.1001/jama.296.15.1867. PMID: 17047219.

  4. Bione S, D'Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5. is responsible for Barth syndrome. Nat Genet. 1996;12(4):385-389. DOI: 10.1038/ng0496-385. PMID: 8630491.

  5. Richards AA, Santos LJ, Nichols HA, et al. Cryptic chromosomal abnormalities identified in children with congenital heart disease. Pediatr Res. 2008;64(4):358-363. DOI: 10.1203/PDR.0b013e31818095d7. PMID: 18552706.

  6. Moller JH, Fisch RO. Endocardial fibroelastosis occurring in a mother and son. Pediatrics. 1966;38(6):918-924. PMID: 5336023.

  7. Kucera F, Hecke F, Mihatsch MJ, et al. Endocardial fibroelastosis: pathomorphological features and association with chromosomal abnormalities. Pediatr Cardiol. 2013;34(4):976-986. DOI: 10.1007/s00246-012-0561-5. PMID: 23160996.

  8. Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail. 2012;18(6):459-470. DOI: 10.1016/j.cardfail.2012.03.001. PMID: 22633313.

  9. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115(6):773-781. DOI: 10.1161/CIRCULATIONAHA.106.621185. PMID: 17261660.

  10. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647-1655. DOI: 10.1056/NEJMoa021715. PMID: 12711739.